ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KOOL Cesca Therapeutics Inc

5.14
0.00 (0.00%)
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 3.30
Ask Price 5.22
News -
Company Name Stock Ticker Symbol Market Type
Cesca Therapeutics Inc KOOL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 5.14 20:00:00
Open Price Low Price High Price Close Price Prev Close
5.14
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 5.14 USD

Cesca Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.33M 1.04M - 10.48M -11.27M -10.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cesca Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KOOL Message Board. Create One! See More Posts on KOOL Message Board See More Message Board Posts

Historical KOOL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Cesca Therapeutics Description

Cesca Therapeutics Inc is clinical-stage biotechnology company. The company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. The company's device division, ThermoGenesis Corp, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca's clinical development division is leveraging its proprietary AutoXpress technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the immuno-oncology, vascular, cardiology and orthopedic markets.

Your Recent History

Delayed Upgrade Clock